<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55400">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01995032</url>
  </required_header>
  <id_info>
    <org_study_id>DMD02</org_study_id>
    <nct_id>NCT01995032</nct_id>
  </id_info>
  <brief_title>L-citrulline and Metformin in Duchenne's Muscular Dystrophy</brief_title>
  <official_title>&quot;A Double Blind Randomised Placebo Controlled Efficacy and Safety Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years With Duchenne's Muscular Dystrophy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to show that the intake of L-citrulline and metformin improves
      muscle function and delay of progression in patients with Duchenne's muscular dystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, double-blind, placebo controlled study. The study
      medication consists of L-citrulline and metformin, respectively placebo given orally; 2.5 g
      L-citrulline or placebo will be given 3 times daily, metformin containing 250 mg or placebo
      will be administered 3 times daily. The duration of the study is 26 weeks and comprehends
      one screening and three study visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean change of motor function measure (MFM) D1 subscore (assessing standing and transfers)</measure>
    <time_frame>baseline to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of MFM total score, the D2, and D3 MFM subscores</measure>
    <time_frame>baseline to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of six minute walking distance (6MWD)</measure>
    <time_frame>baseline to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quantitative muscle MRI (Magnetic Resonance Imaging) including muscle fat content (MFC) and T2 times of thigh muscles</measure>
    <time_frame>baseline to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the plasma/urine concentration for markers of muscle necrosis, oxidative stress, nitrosative stress, and change of microRNA (miRNA)</measure>
    <time_frame>baseline to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of quantitative muscle force (QMT) of knee extension and elbow flexion using hand held dynamometry (HHD)</measure>
    <time_frame>baseline to week 26</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Duchenne's Muscular Dystrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>metformin and L-citrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 g L-citrulline p.o. and 750 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 26 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>750 mg metformin and 7.5 g L-citrulline daily p.o.</intervention_name>
    <arm_group_label>metformin and L-citrulline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Molecular diagnosis of DMD

          -  Patients 7 - 10 years of age at time of screening

          -  Ambulant

          -  Ability to walk 150 m in the 6 min walking distance (6MWT)

          -  D1 subdomain of the MFM scale &gt;40%

          -  stable treatment with steroids for &gt;6 months or steroid na√Øve patients

        Exclusion Criteria:

          -  Previous (3 months or less) or concomitant participation in another      therapeutic
             trial

          -  Use of L-citrulline, L-arginine or metformin within the last 3 months

          -  Known individual hypersensitivity to L-citrulline or metformin

          -  known or suspected malignancy

          -  Other chronic disease or clinical relevant limitation of renal, liver, heart function
             according to discretion of investigator

          -  start of cortisone treatment or change in dosage &lt;6 months prior to screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Fischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ulrike Bonati, MD</last_name>
    <phone>+41617042243</phone>
    <email>ulrike.bonati@ukbb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Rubino</last_name>
    <email>daniela.rubino@ukbb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Bonati, MD</last_name>
      <email>ulrike.bonati@ukbb.ch</email>
    </contact>
    <investigator>
      <last_name>Dirk Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrike Bonati, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne's muscular dystrophy</keyword>
  <keyword>DMD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
